EPS for Amicus Therapeutics, Inc. (FOLD) Expected At $-0.30; INSYS Therapeutics, Inc. (INSY) Covered By 4 Bullish Analysts Last Week

February 17, 2018 - By Nellie Frank

Analysts expect Amicus Therapeutics, Inc. (NASDAQ:FOLD) to report $-0.30 EPS on March, 7.They anticipate $0.02 EPS change or 6.25% from last quarter’s $-0.32 EPS. After having $-0.41 EPS previously, Amicus Therapeutics, Inc.’s analysts see -26.83% EPS growth. The stock decreased 4.17% or $0.66 during the last trading session, reaching $15.17. About 11.01 million shares traded or 306.16% up from the average. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has risen 12.45% since February 17, 2017 and is uptrending. It has underperformed by 4.25% the S&P500.

Among 6 analysts covering Insys Therapeutics (NASDAQ:INSY), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Insys Therapeutics had 22 analyst reports since August 4, 2015 according to SRatingsIntel. RBC Capital Markets maintained the stock with “Buy” rating in Friday, October 27 report. The firm has “Buy” rating by Jefferies given on Wednesday, February 24. The stock has “Buy” rating by Jefferies on Tuesday, April 12. RBC Capital Markets maintained it with “Buy” rating and $1600 target in Thursday, June 1 report. The firm earned “Buy” rating on Monday, October 9 by RBC Capital Markets. The rating was maintained by Piper Jaffray on Tuesday, July 25 with “Hold”. Jefferies maintained the shares of INSY in report on Friday, June 9 with “Buy” rating. The rating was maintained by Jefferies on Monday, October 10 with “Buy”. As per Thursday, September 22, the company rating was maintained by RBC Capital Markets. The rating was maintained by RBC Capital Markets with “Buy” on Thursday, August 3. See INSYS Therapeutics, Inc. (NASDAQ:INSY) latest ratings:

03/11/2017 Broker: Jefferies Rating: Buy Old Target: $14 New Target: $11 Maintain
27/10/2017 Broker: RBC Capital Markets Rating: Buy New Target: $8.0 Maintain
18/10/2017 Broker: Jefferies Rating: Buy New Target: $14.0 Maintain
09/10/2017 Broker: RBC Capital Markets Rating: Buy New Target: $14.0 Maintain
15/09/2017 Broker: Jefferies Rating: Buy New Target: $14.0 Maintain

The stock decreased 3.83% or $0.31 during the last trading session, reaching $7.79. About 636,945 shares traded. INSYS Therapeutics, Inc. (NASDAQ:INSY) has declined 5.69% since February 17, 2017 and is downtrending. It has underperformed by 22.39% the S&P500.

Investors sentiment increased to 1.25 in 2017 Q3. Its up 0.05, from 1.2 in 2017Q2. It improved, as 20 investors sold INSYS Therapeutics, Inc. shares while 20 reduced holdings. 19 funds opened positions while 31 raised stakes. 18.21 million shares or 3.74% more from 17.56 million shares in 2017Q2 were reported. 88,800 are held by Oz Lp. Invesco owns 703,962 shares. Cambridge Inv Advsr Inc accumulated 0% or 40,394 shares. Strs Ohio has invested 0.01% in INSYS Therapeutics, Inc. (NASDAQ:INSY). Panagora Asset Management accumulated 0% or 108,416 shares. Zacks Inv Mgmt reported 0% stake. Voya Invest Mngmt Lc reported 0% of its portfolio in INSYS Therapeutics, Inc. (NASDAQ:INSY). Dekabank Deutsche Girozentrale stated it has 0% of its portfolio in INSYS Therapeutics, Inc. (NASDAQ:INSY). Regal Inv Ltd Limited Liability Company invested 0.33% in INSYS Therapeutics, Inc. (NASDAQ:INSY). Mirae Asset Global, a Korea-based fund reported 1.03 million shares. State Street Corporation invested in 0% or 474,181 shares. Goldman Sachs Gp invested in 0% or 133,839 shares. Orbimed Advisors Lc holds 6.17M shares or 0.52% of its portfolio. Northern Tru holds 0% or 313,211 shares in its portfolio. Proshare Ltd Co invested in 0% or 42,596 shares.

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company has market cap of $571.14 million. The firm markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. It currently has negative earnings. The Company’s lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS.

Among 9 analysts covering Amicus Therapeutics (NASDAQ:FOLD), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Amicus Therapeutics had 22 analyst reports since August 18, 2015 according to SRatingsIntel. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) earned “Buy” rating by Zacks on Tuesday, August 18. The firm earned “Buy” rating on Tuesday, September 1 by Cowen & Co. The company was upgraded on Monday, October 5 by Chardan Capital Markets. Robert W. Baird maintained Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Wednesday, July 12 with “Outperform” rating. The firm has “Buy” rating by Janney Capital given on Tuesday, March 8. Leerink Swann maintained the stock with “Outperform” rating in Monday, October 5 report. On Tuesday, January 24 the stock rating was upgraded by Robert W. Baird to “Outperform”. On Monday, August 7 the stock rating was maintained by Cowen & Co with “Buy”. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) earned “Neutral” rating by Chardan Capital Markets on Wednesday, September 16. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) has “Buy” rating given on Tuesday, July 11 by Cowen & Co.

Investors sentiment increased to 2.33 in 2017 Q3. Its up 1.10, from 1.23 in 2017Q2. It increased, as 16 investors sold Amicus Therapeutics, Inc. shares while 32 reduced holdings. 52 funds opened positions while 60 raised stakes. 192.70 million shares or 14.18% more from 168.77 million shares in 2017Q2 were reported. Sectoral Asset Mgmt Inc, Quebec – Canada-based fund reported 2.41M shares. Thompson Davis & holds 0.01% or 375 shares. Nicholas Invest Prtnrs L P holds 0.14% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 134,388 shares. Franklin holds 3.31 million shares. Voya Investment Management Limited Liability Company owns 76,119 shares or 0% of their US portfolio. Trexquant Lp stated it has 0.08% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD). State Street owns 8.15 million shares. Berson & Corrado Invest Advsrs Lc reported 0.29% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Mutual Of America Cap Mngmt Limited Liability Corp accumulated 78,400 shares or 0.02% of the stock. Neuberger Berman Group Llc owns 13,000 shares or 0% of their US portfolio. Credit Suisse Ag reported 913,742 shares. California State Teachers Retirement accumulated 264,569 shares. Blackrock accumulated 0.01% or 13.37 million shares. Ubs Asset Mngmt Americas Incorporated reported 64,152 shares. Dekabank Deutsche Girozentrale owns 0.01% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 70,900 shares.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>